Characterization of a *Lactobacillus brevis* strain with potential oral probiotic properties

Fang Fang, Jie Xu, Qiaoyu Li, Xiaoxuan Xia and Guocheng Du

**Abstract**

**Background:** The microflora composition of the oral cavity affects oral health. Some strains of commensal bacteria confer probiotic benefits to the host. *Lactobacillus* is one of the main probiotic genera that has been used to treat oral infections. The objective of this study was to select lactobacilli with a spectrum of probiotic properties and investigate their potential roles in oral health.

**Results:** An oral isolate characterized as *Lactobacillus brevis* BBE-Y52 exhibited antimicrobial activities against *Streptococcus mutans*, a bacterial species that causes dental caries and tooth decay, and secreted antimicrobial compounds such as hydrogen peroxide and lactic acid. Compared to other bacteria, *L. brevis* BBE-Y52 was a weak acid producer. Further studies showed that this strain had the capacity to adhere to oral epithelial cells. Co-incubation of *L. brevis* BBE-Y52 with *S. mutans* ATCC 25175 increased the IL-10-to-IL-12p70 ratio in peripheral blood mononuclear cells, which indicated that *L. brevis* BBE-Y52 could alleviate inflammation and might confer benefits to host health by modulating the immune system.

**Conclusions:** *L. brevis* BBE-Y52 exhibited a spectrum of probiotic properties, which may facilitate its applications in oral care products.

**Keywords:** *Lactobacillus brevis*, Antimicrobial activity, Hydrogen peroxide, Adhesion, Immunomodulation

**Background**

Oral infectious diseases, such as dental caries and periodontal diseases, represent one of the most common infections that severely impact human health [1]. As a result of antibiotics overuse and misuse and the emergence of antibiotic-resistant strains, probiotic therapy has been gradually applied to prevent and alleviate infectious diseases [2–4]. *Lactobacillus* is one of the main probiotic genera that has been widely studied for its potential roles on oral health. Evidence shows that consumption of milk enriched with *Lactobacillus rhamnosus* GG decreases the risk of dental caries in children [5]. Similarly, *Lactobacillus reuteri* reduces the risk of gingivitis [6]. Therefore, lactobacilli with probiotic properties may prevent the colonization of oral pathogens through different mechanisms.

Probiotic strains produce antimicrobial components such as hydrogen peroxide and lactic acid, which inhibit the growth of oral pathogens (e.g., *Streptococcus mutans*). However, excessive acid production by lactobacilli may result in the demineralization of the tooth enamel and contribute to dental caries [7]. Moreover, auto-aggregation of the same strain, co-aggregation with common oral strains, and production of extracellular polysaccharides by probiotics favor the formation of biofilms, which protect bacterial strains against environmental changes and contribute to cell aggregation and colonization [8, 9]. The adhesion of strains to oral epithelial cells prevents the colonization of pathogens [10]. The modulation of the immune system by probiotics, which affects human health, is assessed by the release of anti-inflammatory cytokine interleukin (IL)-10 and pro-inflammatory cytokine IL-12p70. Strains with high
IL-10-to-IL-12p70 ratios confer benefits to human health [11].

The aim of this study was to characterize Lactobacillus strains with potential probiotic properties including production of antimicrobial compounds and extracellular polysaccharides and the capability to adhere to oral epithelial cells.

Results
Isolation of lactobacilli with antimicrobial activity
We analyzed 32 oral isolates. Among them, one Lactobacillus strain isolated from dental plaque exhibited antimicrobial activities against S. mutans ATCC 25175 (Fig. 1). This strain was identified with 16S rRNA gene and pheS sequence blast and designated L. brevis BBE-Y52. In addition to bacteriocin, hydrogen peroxide is another antimicrobial compound that inhibits bacterial growth. Production of hydrogen peroxide is rare in Lactobacillus due to their weak tolerance to oxygen. However, L. brevis BBE-Y52 produced 0.06–0.15 mM hydrogen peroxide. Lactic acid is another antimicrobial compound that is produced by almost all lactobacilli. Production of lactic acid is necessary for the inhibition of oral pathogens; however, excessive acid production may result in tooth decay. Therefore, we measured the capacity of L. brevis BBE-Y52 to produce acid and compared it to other lactic acid bacteria. We observed that L. brevis BBE-Y52 was a weak acid producer compared with Lactobacillus salivarius T1 and S. mutans ATCC 25175, based on the difference in average pH values when cultivated in MRS broth supplemented with various carbon sources (Table 1). Moreover, the final concentration of lactic acid from L. brevis BBE-Y52 (1.74 ± 0.12 g/L) in the broth was lower than that from L. salivarius T1 and S. mutans ATCC 25175 (2.64 ± 0.09 and 2.53 ± 0.07 g/L, respectively).

L. brevis BBE-Y52 susceptibility to lysozyme, hydrogen peroxide, and antibiotics
Microorganisms in the oral cavity may be affected by lysozyme and hydrogen peroxide. We measured the L. brevis BBE-Y52 resistance to lysozyme and hydrogen peroxide. L. brevis BBE-Y52 showed tolerance to 1.0 mg/mL lysozyme, which is much higher than that present in the oral cavity [12]. The L. brevis BBE-Y52 tolerance to hydrogen peroxide was 2.0 mM (Fig. 2). L. brevis BBE-Y52 was resistant to kanamycin and streptomycin and susceptible to ampicillin, tetracycline, and chloramphenicol (Table 2).

Evaluation of the aciduric profile of L. brevis BBE-Y52
Resistance to acid stress is a very important trait for probiotics and may help them to survival in harsh niches and therefore expand their applications. In this study, resistance of L. brevis BBE-Y52 to acid stress was examined, and the aciduric profile of it was compared with that of two Lactobacillus strains (L. casei DSM 20011 and an oral isolate L. paracasei XJ02). As shown in Fig. 3, the survival rate of L. brevis BBE-Y52 is higher than that of L. casei DSM 20011 and L. paracasei XJ02 at both pH 2.0 and pH 3.0. After 3 h exposure to pH 2.0, no viable cell counts were determined for L. casei DSM 20011, while the survival rate for L. brevis BBE-Y52 and L. paracasei XJ02 were 0.027% (3.6 log cycles reduction in viable cell numbers) and 0.014% (3.9 log cycles reduction in viable cell numbers), respectively.

Biofilm formation and adhesion of L. brevis BBE-Y52 to KB cells
Biofilms confer protection to microorganisms against environmental changes. Both EPS production and aggregation of bacteria contribute to biofilm formation. L. brevis BBE-Y52 formed viscous colonies and produced 106.6 mg/L EPS.

The ability of L. brevis BBE-Y52 to auto-aggregate and aggregate with other bacteria was investigated and compared with that of oral pathogens including Streptococcus mutans, Porphyromonas gingivalis and Fusobacterium nucleatum. All tested strains exhibited a capacity to auto-aggregate after 3 h incubation (Fig. 4). The L. brevis BBE-Y52 auto-aggregation capacity was higher than that of all tested strains except S. mutans ATCC 25175. L. brevis BBE-Y52 exhibited co-aggregation with all tested strains, reduced S. mutans ATCC 25175 aggregation significantly, and slightly reduced P. gingivalis GIM 1.851 and F. nucleatum CGMCC 1.2528 aggregation. Formation of mature biofilm by L. brevis BBE-Y52 and S. mutans ATCC 25175 was observed following 24 h incubation. S. mutans ATCC 25175 exhibited a stronger capacity for biofilm formation than L. brevis BBE-Y52. Co-culture of L.
**L. brevis** BBE-Y52 effects on cytokine production by human PBMCs

Immunomodulation is an important mechanism that affects human health. Strains with immunomodulatory properties are desirable. Therefore, *L. brevis* BBE-Y52 immunomodulatory properties were evaluated by measuring the release of cytokines, including pro-inflammatory IL-12p70 and anti-inflammatory IL-10. In the model of cellular immunity analysis, *S. mutans* ATCC 25175 caused inflammation in PBMCs, indicated by the decreased IL-10-to-IL-12p70 ratio. Co-culturing of PBMCs with *L. brevis* BBE-Y52 increased IL-10 levels and decreased the IL-10-to-IL-12p70 ratio (Table 3). In *S. mutans* ATCC 25175-inflamed PBMCs, *L. brevis* BBE-Y52 significantly increased the IL-10-to-IL-12p70 ratio from 4.1 to 3.8, suggesting that *L. brevis* BBE-Y52 could alleviate inflammation in PBMCs (Table 3).

**Discussion**

Lactobacilli with probiotic properties have been used in clinical trials due to their role in oral health [13–16], *Lactobacillus crispatus*, *Lactobacillus fermentum*, and *Lactobacillus gasseri* (oral isolates) and *L. rhamnosus* LGG (a non-oral isolate) have oral probiotic properties including reduction of oral pathogens counts and adherence to oral epithelial cells [17, 18]. In this study, *L. brevis* BBE-Y52, a strain isolated from the dental plaque of a healthy donor, exhibited oral probiotic properties such as inhibition of the oral pathogen species *S. mutans*, reduction of aggregation of *S. mutans*, *P. gingivalis* and *F. nucleatum*, production of hydrogen peroxide, resistant to acidic condition, adherence to KB cells, and alleviation of inflammation. This is the first time that a *Lactobacillus* strain is shown to have so many composite oral

---

**Table 1** Acid production by *Lactobacillus brevis* BBE-Y52, *Lactobacillus salivarius*, and *Streptococcus mutans*

| Strains                  | pH<sup>a</sup> | Lactic acid<sup>c</sup> (g/L) | Average pH<sup>b</sup> | Glucose | Sucrose | Lactose | Fructose |
|-------------------------|----------------|-------------------------------|------------------------|---------|---------|---------|---------|
| *L. brevis* BBE-Y52     | 3.85 ± 0.01    | 4.02 ± 0.03                   | 4.07 ± 0.02*           | 3.77 ± 0.03 | 3.93*   | 1.74 ± 0.12** |
| *L. salivarius* T1      | 3.81 ± 0.03    | 3.90 ± 0.04                   | 3.98 ± 0.02            | 3.80 ± 0.02 | 3.87   | 2.64 ± 0.09   |
| *S. mutans* ATCC 25175  | 3.90 ± 0.02*   | 3.87 ± 0.03*                  | 3.95 ± 0.01            | 3.74 ± 0.03 | 3.86   | 2.53 ± 0.07   |

<sup>a</sup> pH values of strain cultures grown in medium containing single carbon source; <sup>b</sup> average pH values; <sup>c</sup> production of lactic acid by corresponding strains cultivated in MRS broth

* and ** represent significant (*P* < 0.05) and extremely significant (*P* < 0.01) differences based on Student’s t-test

---

**Fig. 2** Tolerance of *Lactobacillus brevis* BBE-Y52 to hydrogen peroxide
probiotic properties, which indicating the potential applications (inhibition or exclusion of oral pathogens, persistence in oral cavity, anti-inflammation) of *L. brevis* BBE-Y52 in oral care products.

It has been shown that a few *Lactobacillus* strains exhibited capability of inhibition oral pathogens. *L. rhamnosus* LGG, a human probiotic, reduces the counts of oral pathogens *Streptococcus sanguinis* and *Candida albicans* and reduces the biofilm-forming ability of *Fusobacterium nucleatum*, an oral bacterium associated with periodontal disease [18]. Mishra et al. demonstrated that a probiotic rinse (containing *Streptococcus*) was as effective as a chlorhexidine digluconate rinse in reducing *C. albicans* counts [19]. *Lactobacillus* strains isolated from the oral cavity showed antibacterial activity against the periodontal pathogen *Porphyromonas gingivalis*, but they did not inhibit the growth of *Prevotella intermedia* or *S. mutans* when the acid effect was removed [17]. Lactic acid produced by lactic acid bacteria inhibits the growth of Gram-negative bacteria including the oral pathogen *P. gingivalis* [20]. In this study, the antimicrobial activity of *L. brevis* BBE-Y52 against *S. mutans* was confirmed after removing the lactic acid effect (Fig. 1). This probiotic might inhibit the growth of other oral pathogens. However, lactic acid may potentially weaken the tooth enamel [7]. Therefore, a weak lactic acid producer is more suitable for oral care products. Compared to other *Lactobacillus* strains tested in this study and those previously reported (*Lactobacillus acidophilus* CRL 1259 and *Lactobacillus* strain L1 and L2 produce 8.57–9.28 and 8.85 g/L lactic acid, respectively) [21, 22], *L. brevis* BBE-Y52 is a weak lactic acid producer. Moreover, *L. brevis* BBE-Y52 survives better at pH 2.0 and pH 3.0 than other two tested *Lactobacillus* strains (Fig. 3). After 3 h treatment at pH 2.0, the viable cell number of *L. brevis* BBE-Y52 is 3.6 log cycles reduction, this is much better than that of 90% probiotic *Lactobacillus* strains (1.5–9.0 log cycles reduction) [23]. Hydrogen peroxide is another antimicrobial substance that can be produced by streptococci and some commensal lactobacilli [24]. *L. brevis* BBE-Y52 produced up to 0.15 mM hydrogen peroxide when grown in MRS broth in microaerobic conditions. This is lower than that of the intestine isolate *Lactobacillus johnsonii* NCC 533, which produces 1 mM hydrogen peroxide when cultivated in LAPTg medium under aerobic conditions [24]. *L. brevis* BBE-Y52 is competitive, because *L. johnsonii* NCC 533 hardly produces any hydrogen peroxide in anaerobic conditions [24].

In this study, the co-aggregation with *L. brevis* BBE-Y52 decreased *S. mutans* *P. gingivalis* and *F. nucleatum* aggregation (Fig. 4), which may in part reduce the risk of dental caries and periodontal disease. The capacity to co-aggregate with oral microbes and form biofilms may contribute to *L. brevis* BBE-Y52 colonization.
in the oral cavity. In addition, the adherence ratio of *L. brevis* BBE-Y52 to KB cells was (15 ± 2): 1, which demonstrated that *L. brevis* BBE-Y52 has the capacity to adhere to KB cells, based on classification criteria [25]. Saeed and Heczko demonstrated that lactobacilli with high auto-aggregation are highly adherent to the KB cell line [26], consistent with our findings. *Lactobacillus* strains of oral origin adhered to oral epithelial cells with an adherence of 60 bacterial cells/mm² for HO and/or HSC cells [17]. According to MIC analysis, *L. brevis*
BBE-Y52 is resistant to kanamycin and streptomycin, but susceptible to ampicillin, chloramphenicol and tetracycline. In contrast, Lactobacillus plantarum and Lactobacillus oris strains are resistant to tetracycline [27, 28]. L. brevis BBE-Y52 tolerates 1 mg/mL lysozyme, some oral lactobacilli tolerate up to 10 mg/mL lysozyme [28], while L. plantarum strains tolerate up to 0.1 mg/mL lysozyme [29]. Immunomodulation by probiotics is an important aspect that confers benefits on human health. Immunomodulation can be evaluated by the release of cytokines as key regulators. Following co-incubation of inflamed PBMCs (by S. mutans) with L. brevis BBE-Y52, inflammation subsided based on the increase in IL-10-to-IL-12p70 ratio (Table 2).

### Methods

#### Strains and growth conditions

Lactobacillus strains were grown in de man, Rogosa, Sharpe (MRS, OXO, Hampshire, UK) medium and incubated at 37 °C under microaerophilic conditions (5% CO₂) for 24–48 h. S. mutans ATCC 25175 was grown in brain heart infusion medium (BHI, Oxoid, Hampshire, UK) at 37 °C under microaerophilic conditions. *Porphyromonas gingivalis* GIM1.851 and *Fusobacterium nucleatum* CGMCC 1.2528 were grown at 37 °C anaerobically in brain heart infusion medium (BHI, Oxoid, Hampshire, UK) at 37 °C under microaerophilic conditions.

#### Lactobacilli isolation and identification from human saliva and dental plaques

Human saliva and dental plaques samples of 10 healthy donors (five female and five male; mean age 24 ± 3 years) were obtained from Wuxi No. 2 People's Hospital (Wuxi, Jiangsu Province, China) according to the method reported by Krajden [30]. Lactobacillus strains were isolated by plating the serial diluted samples on MRS agar and cultured at 37 °C under microaerophilic conditions.

Genomic DNA of *Lactobacillus* strains were extracted using EZNA genomic DNA isolation kits (Omega Bio-Tek, Doraville, USA). Strains were identified by analysis of 16S rDNA (amplified by primers 16SF 5’-TACGGYTACC TTGGTACGACTT-3’ and 16SR 5’-AGAGTTTGATCMT TGCTCAG-3’) and pheS (amplified by primers pheSF 5’-TCCCATTTACGGAGCCTTCTG-3’ and pheSR 5’-GCACCATACGGGCACCTAACAC-3’) sequences and blasted against the NCBI database.

#### Antimicrobial activity assay

Antimicrobial activities of isolates against S. mutans ATCC 25175 were evaluated by the agar well-diffusion method [31]. Briefly, 10 mL of base agar (1.5%, w/v) was plated on a Petri dish and allowed to cool before placing on sterile Oxford Cups. *S. mutans* ATCC 25175 (final concentration in agar: 10⁶ CFU/mL) was mixed with 10 mL of semi-solid BHI agar (0.8%, w/v) and overlaid on the base agar. Oxford Cups were removed when the upper layer set. Finally, 100 μL of supernatant of bacterial culture or heat-inactivated supernatant (control) was added to wells and incubated at 37 °C (5% CO₂) for 24 h. The inhibition zones represent the growth inhibition of *S. mutans* ATCC 25175 by corresponding strains.

#### Analysis of acid production

*Lactobacillus* strains and *S. mutans* were inoculated in MRS broth (devoid of carbon source) supplemented with single carbon source (equal moles of glucose, sucrose, lactose, and fructose) and grown at 37 °C and 5% CO₂ for 24 h. Following a 24-h incubation, the pH value of the broth was measured. Production of lactic acid by these strains grown in MRS at 37 °C (5% CO₂) for 24 h was determined with high performance liquid chromatography using a modified method [32]. Strains were removed by centrifugation at 10,000 rpm for 10 min. Corresponding supernatants were passed through a 0.22-μm membrane filter, and 20 μL of the filtrate or its dilution was injected onto HPLC for lactic acid quantification. Separation was performed using an HPLC organic acid analysis column (300 mm x 7.8 mm, BIO-RAD, Hercules, CA, USA) at 40 °C, using 0.05 mM sulfuric acid as the mobile phase (flow rate 0.6 mL/min, 30 min). Lactic acid was detected at 210 nm.

#### Detection of acid resistance of *Lactobacillus*

*L. brevis* BBE-Y52, *L. casei* DSM 20011 and *L. paracasei* XJ02 (a strain isolated from oral cavity, this study) were grown in MRS broth at 37 °C. Cells of these strains collected during the exponential growth phase were harvested by centrifugation (8000 rpm, 5 min), and then washed three times with phosphate buffer saline (PBS, pH 7.2) before suspended in PBS or PBS adjusted to pH 2.0 and 3.0 using 5 M HCl, and incubated at 37 °C. Samples of each solution were taken at different time points.

### Table 3 PBMC cytokine levels in response to co-culturing with *L. brevis* BBE-Y52 or *S. mutans*

| Cytokine | Control BBE-Y52 | BBE-Y52 | S. mutans | Control BBE-Y52 | BBE-Y52 |
|----------|----------------|---------|-----------|----------------|---------|
| IL-10 (pg mL⁻¹) | 164 ± 2 | 186 ± 2 | 177 ± 4 | 248 ± 2 | 243 ± 3 |
| IL-12p70 (pg mL⁻¹) | 28 ± 2 | 31 ± 1 | 33 ± 1 | 65 ± 2 | 59 ± 2 |
| IL-10/IL-12p70 | 5.8 ± 0.2 | 6.1 ± 0.1* | 5.4 ± 0.1* | 3.8 ± 0.1 | 4.1 ± 0.1* |

* PBMCs incubated either alone (control) or with BBE-Y52/S. mutans for 12 h; ** IL-10-to-IL-12p70 ratio was significant (P < 0.05) based on Student's t-test.
Detection of extracellular polysaccharides (EPS) and hydrogen peroxide
Bacterial strains were grown on MRS agar containing 10% (w/v) sucrose, and the plates were incubated at 30 °C for 48 h. Strains that appeared as viscous colonies were considered to be EPS producers [33]. For quantitative analysis of EPS, strains were grown at 30 °C for 48 h in MRS broth containing 10% (w/v) sucrose. Proteins in cultures were precipitated with trichloroacetic acid (Sigma–Aldrich, St. Louis, MO, USA) and stirred for 30 min on ice. Following centrifugation at 15,000 g for 30 min at 4 °C, cold ethanol (three times the volume) was added to the supernatant and stored overnight at 4 °C to precipitate EPS. The sediment was collected by centrifugation at 15,000 g for 30 min at 4 °C and dissolved in distilled water. EPS was determined by phenol–sulfuric acid method using D-glucose as a standard [34].

To measure hydrogen peroxide production, bacterial strains were grown in MRS broth and incubated at 37 °C (5% CO₂) for 24 h. Hydrogen peroxide in cell-free supernatant of corresponding bacterial cultures was measured using semi-quantitative test strips (Merck, Poole, UK), which detect hydrogen peroxide at 0 to 25 mg/L.

Lysozyme, hydrogen peroxide, and antibiotic susceptibility
The susceptibility of lactobacilli (10⁷ CFU/mL) to lysozyme (Thermo Fisher, Waltham, MA, USA) was examined by an agar well-diffusion method [28]. Susceptibility to hydrogen peroxide (Sigma–Aldrich) was evaluated by the survival of the corresponding strain when exposed to hydrogen peroxide [35]. The Lactobacillus strain was cultivated in MRS at 37 °C (5% CO₂) for 24 h. Cells were harvested by centrifugation (8000 rpm, 15 min) and rinsed twice with phosphate-buffered saline (PBS, pH 7.0) before re-suspending (10⁸ CFU/mL) in PBS containing 0–2 mM hydrogen peroxide at 37 °C (5% CO₂) for 1 h. Corresponding cultures were plated in MRS agar, and viable cells were counted and compared with the control (0 mM hydrogen peroxide). Survival rate was calculated to evaluate the resistance to hydrogen peroxide. Antibiotic susceptibility of lactobacilli was determined by the disk diffusion method [36]. Strains were classified as resistant or susceptible by comparing the minimum inhibitory concentrations of antibiotics (Sigma–Aldrich) with European Food Safety Authority standards [37].

Aggregation assays
Bacterial aggregation of single strain (auto-aggregation) and two strains were examined [38, 39]. Cells of S. mutans ATCC 25175, P. gingivalis GIM1.851 and F. nucleatum CGMCC 1.2528 collected during the exponential growth phase were harvested, cells were washed twice with PBS, and suspended in PBS to an OD₆₀₀ value of 0.5 (A₀). Absorbance at 600 nm of the upper suspension (Aₓ) was measured after 1–3 h incubation. Coaggregations of oral lactobacilli with the foregoing strains were determined by combining equal volumes (500 μL) of the adjusted suspensions of isolates (Aₚrobio) and oral pathogens (Aₚat). Coaggregation was calculated using the formula described by Collado [38].

\[
\text{Auto-aggregation} \% = (A₀ - Aₓ)/A₀ \times 100.
\]
\[
\text{Coaggregation} \% = [(Aₚat + Aₚrobio)/2 - Aₚrobio]/(Aₚat + Aₚrobio)/2 \times 100.
\]

where Aₚrobio represents absorbance at 600 nm of culture of two strains.

Biofilm formation assays
The formation of biofilm by oral isolates and S. mutans ATCC 25175 was assessed using the microtiter plate method [40]. Lactobacillus strains and S. mutans were cultivated in MRS or BHI at 37 °C (5% CO₂) for 24 h. Subsequently, 125 μL of cell suspensions (OD₆₀₀ = 1.0) of individual strains were added to wells of a 24-well plate containing 875 μL BHI broth (750 μL BHI broth for two strains), and incubated at 37 °C (5% CO₂) for 12–36 h. Cell suspensions were removed by careful pipetting. Wells were rinsed three times with PBS and air-dried for 30 min. Wells were stained with crystal violet (1%, w/v) for 20 min, rinsed with PBS, and air-dried for 30 min. Ethanol (1 mL, 95%) was added, and absorbance at 570 nm was measured.

Adhesion assays
The oral epithelial carcinoma cell line (KB) was used to assess the adhesion of oral lactobacilli [41, 42]. KB cells (provided by Prof. Jian Jin, and purchased from ATCC, Manassas, VA, USA) were grown in minimum essential medium (MEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (Invitrogen) at 37 °C (5% CO₂). A concentration of 3.0 × 10⁷ KB cells was seeded in 35-mm-diameter dishes (Corning, New York, NY, USA) and incubated until the formation of a complete monolayer. The KB cells monolayer was washed twice with PBS, and an aliquot of 2 mL minimal essential medium (MEM, Invitrogen) was added to the plates and incubated at 37 °C (5% CO₂) for 30 min. The bacterial cultures were washed and suspended in MEM (10⁵ CFU/mL). Bacterial suspension (120 μL) was seeded onto the KB cells monolayer and incubated for 1 h at 37 °C (5% CO₂). The KB cells monolayer were subsequently washed to remove unattached bacteria. Methanol (3 mL) was added to fix the cells (10 min) and removed prior to staining with 3 mL Giemsa stain for
30 min. For detecting the adhesion of lactobacilli to KB cells, the dishes were rinsed, dried at 37°C for 16 h, and examined by microscopy [42]. To quantify the adhesion capability of bacteria to KB cells, the monolayers were lysed with distilled water. Corresponding solutions were plated on MRS, and viable adherent bacteria were counted. Adhesive capacity was determined according to the number of strains that adhered to one KB cell [41].

Effects of lactobacilli on cytokine production by human peripheral blood mononuclear cells (PBMCs)

PBMCs were isolated from the donors’ peripheral blood by Ficoll gradient centrifugation. PBMCs (2 × 10⁶ cell/mL) were incubated at 37°C (5% CO₂) for 2 h and then incubated alone (the control) or with either S. mutans ATCC 25175 (10⁵ CFU/mL) or oral lactobacilli (10⁶ CFU/mL) for 12 h at 37°C (5% CO₂). The suspensions in the wells were aspirated and washed with RPMI 1640 medium (Thermo Fisher, Shanghai, China). For the double-challenge, S. mutans ATCC 25175-stimulated PBMCs (2 × 10⁶ cell/mL) were incubated either alone or with oral lactobacilli (10⁶ CFU/mL) for 24 h prior to cytokine analysis [11]. The production of anti-inflammatory IL-10 cytokine and pro-inflammatory IL-12p70 cytokine were determined by enzyme linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA).

Statistical analysis

All experiments were performed in triplicate. Results were analyzed using Student’s t-test by SPSS 19.0. Statistical significance was set at P < 0.05.

Abbreviations

CFU: Colony forming unit; DNA: Deoxyribonucleic acid; ELISA: Enzyme linked immunosorbent assay; EPS: Extracellular polysaccharides; IL: Human peripheral blood mononuclear cells; cytotoxicity; MRS: De man, Rogosa, Sharpe; PBS: Phosphate buffered saline; PYG: Peptide yeast glucose; TSB: Tryptone soy broth

Acknowledgements

We are grateful to Dr. Jian Zhang from Wuxi No. 2 People’s Hospital for his assistance with the oral samples, and Prof. Jian Jin (Jiangnan University) for providing the oral epithelial carcinoma cell line (KB).

Funding

This research was supported by the National Natural Science Foundation of China (31771955) and the Program for Changjiang Scholars and Innovative Research Team (No. IRT_15R26). The funding sources had no role in the design of the study and collection, analysis, and interpretation of data, or preparation of the manuscript.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Authors’ contributions

FF, GD designed the experiments and wrote the manuscript; FF, GD have contributed to the acquisition, analysis and interpretation of the data; JX, QL, XX performed the experiments and participated to the interpretation of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the ethics committee of Jiangnan University. The written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China. 2. State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi 214122, China. 3. The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi 214122, China.

Received: 3 January 2018 Accepted: 10 December 2018

Published online: 22 December 2018

References

1. Çağlar E, Kargul B, Tanboga I. Bacteriotherapy and probiotics’ role on oral health. Oral On. 2005;11(5):131–7.
2. Oo KM, Lwin AA, Kyaw YY, Tun WM, Fukada K, Goshima A, et al. Safety and long-term effect of the probiotic FK-23 in patients with hepatitis C virus infection. Biosci Biomedi Food Health. 2016;35(3):123–8.
3. Michalidouva D, Minic R, Dikic N, Andjeljkovic M, Kostic-Vucicevic M, Stoimenovic T, et al. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. Appl Physiol Nutr Metab. 2016;41(7):782–9.
4. Karlsson M, Scherbak N, Khalaf H, Olsson PE, Jass J. Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-kappaB activity in Escherichia coli-stimulated urinary bladder cells. FEMS Immunol Med Microbiol. 2012;66(2):147–56.
5. Nase L, Harakka K, Savilaheti E, Saxelin M, Ponka A, Poussa T, et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35(6):412–20.
6. Krasse P, Carlson B, Dahl C, Paulson A, Nilsson A, Sinkiewicz G. Decreased gum bleeding and reduced gingivitis with the probiotic Lactobacillus reuteri. Swed Dent J. 2006;30(2):55–60.
7. Selwitz RH, Israili AJ, Pitts NB. Dental caries. Lancet. 2007;369(9555):236–9.
8. Kolenbrander PE. Oral microbial communities: biofilms, interactions, and genetic systems. Annu Rev Microbiol. 2000;54:413–37.
9. Walter J, Schwab C, Loach DM, Ganzle MG, Tannock GW. Glucosyltransferase of Streptococcus mutans. J Clin Microbiol. 2004;42(11):4563–71.
10. Krasse P, Carlson B, Dahl C, Paulson A, Nilsson A, Sinkiewicz G. Decreased gum bleeding and reduced gingivitis with the probiotic Lactobacillus reuteri. Swed Dent J. 2006;30(2):55–60.
11. Selwitz RH, Israili AJ, Pitts NB. Dental caries. Lancet. 2007;369(9555):236–9.
15. Riccia DN, Bizzini F, Perilli MG, Polimene A, Trinchieri V, Amicosante G, et al. Anti-inflammatory effects of Lactobacillus brevis (CD2) on periodontal disease. Oral Dis. 2007;13(4):376–85.

16. Vicario M, Santos A, Violant D, Nart J, Giner L. Clinical changes in periodontal subjects with the probiotic Lactobacillus reuteri Prodenis: a preliminary randomized clinical trial. Acta Odontol Scand. 2013;71(3–4):813–9.

17. Terai T, Okumura T, Imai S, Nakao M, Yamaji K, Ito M, et al. Screening of probiotic candidates in human oral bacteria for the prevention of dental disease. PLoS One. 2015;10(6):e0128657.

18. Jiang Q, Stamatova I, Kainulainen V, Korpeila R, Meurman JH. Interactions between Lactobacillus rhamnosus GG and oral micro-organisms in an in vitro biofilm model. BMC Microbiol. 2016;16(1):1–11.

19. Migliuca R, Tandon S, Rathore M, Banerjee M. Antimicrobial efficacy of probiotic and herbal oral rinses against Candida albicans in children: a randomized clinical trial. Int J Clin Pediatr Dent. 2016;9(1):25–30.

20. Takahashi N, Schachtelte CE. Effect of pH on the growth and proteolytic activity of Porphyromonas gingivalis and Bacteroides intermedius. J Dent Res. 1990;69:1266–9.

21. Juárez Tomás MS, Ocaña VS, Wiese B, Nader-Macías ME. Growth and lactic acid production by vaginal Lactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli. J Med Microbiol. 2003;52:1117–24.

22. Shokri D, Khorasgani MR, Mohkam M, Fatemi SM, Ghasemi Y, Taheri-Kafrani A. The inhibition effect of lactobacilli against growth and biofilm formation of Pseudomonas aeruginosa. Probiotics Antimicrob. 2018;10(1):34–42.

23. Maragkoudakis PA, Zoumpopoulou G, Miaris C, Kalantzopoulos G, Pot BD, Tsikalidou E. Probiotic potential of Lactobacillus strains isolated from dairy products. Int Dairy J. 2006;16(12):189–99.

24. Hertzberger R, Arents J, Dekker HL, Pridmore RD, Gysler C, Kleerebezem M, et al. H2O2 production in species of the Lactobacillus acidophilus group: a central role for a novel NADH-dependent flavin reductase. Appl Environ Microbiol. 2014;80(7):2229–39.

25. Candela M, Seibold G, Vitali B, Lachenmaier S, Eikmanns BJ, Brigidi P. Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens. Res Microbiol. 2005;156(6):887–95.

26. Saeed A, Heczko PB. Surface properties of lactobacilli isolated from healthy subject. Folia Med Cracov. 2007;48(1–4):99–111.

27. Georgieva R, Yocheva L, Tserovska L, Zhenezova G, Stefanova N, Atanasova A, et al. Antimicrobial activity and antibiotic susceptibility of Lactobacillus and Bifidobacterium spp. intended for use as starter and probiotic cultures. Biotechnol Biotechnol Equip. 2015;29(1):84–91.

28. Koll P, Mandar R, Marcaste H, Leibur E, Mikelsaar M, Hammarstro L. Characterization of oral lactobacilli as potential probiotics for oral health. Oral Microbiol Immun. 2008;23(2):139–47.

29. Yadav R, Puniya AK, Shukla P. Probiotic properties of Lactobacillus plantarum RYPR1 from an indigenous fermented beverage Raabadi. Front Microbiol. 2016;7:1683.

30. Kajden S, Fuksa M, Anderson J, Kempton J, Boccia A, Petrea C, et al. Examination of human stomach biopsies, saliva, and dental plaque for Campylobacter pylori – Oral Microbiol Immun. 2008;23(2):139–47.

31. Fang F, Feng T, Du G, Chen J. Evaluation of the impact on food safety of a Lactobacillus casei strain from pickled vegetables with degradation activity against nitrite and other undesirable compounds. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2016;33(6):623–30.

32. Gezginc Y, Topcal F, Comertpay S, Akyol I. Quantitative analysis of the lactic acid and acetaldehyde produced by Streptococcus thermophilus and Lactobacillus bulgaricus strains isolated from traditional Turkish yogurts using HPLC. J Dairy Sci. 2015;98(3):1426–34.

33. Yang Z, Li S, Zhang X, Zeng X, Li D, Zhao Y, Zhang J. Capsular and slime-poly saccharide production by Lactobacillus rhamnosus JAAS8 isolated from Chinese sauerkraut: potential application in fermented milk products. J Biosci Bioeng. 2010;110(1):53–7.

34. Dubois M, Gilles JK, Hamilton JK, Rebers PA, Smith F. Colorimetric methods for determination of sugars and related substances. Anal Chem. 1956;28:350–6.

35. Kullas T, Zilmer M, Mikelsaar M, Vihalemm T, Annuk H, Kairane C, Kilk A. Two antioxidative lactobacilli strains as promising probiotics. Int J Food Microbiol. 2002;72(3):215–24.

36. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001;48(Suppl 1):S1–6.

37. EFSA. Update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance: EFSA J. 2008;73:2:1–15.